跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

SML3662

Sigma-Aldrich

Etrasimod arginine

≥98% (HPLC)

别名:

APD 334 L-Arginine, L-Arginine mono[(3R)-7-[[4-cyclopentyl-3-(trifluoromethyl)phenyl]methoxy]-1,2,3,4-tetrahydrocyclopent[b]indol-3-yl]acetate, L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C32H40F3N5O5
CAS号:
1206123-97-8
分子量:
631.69
分類程式碼代碼:
12352209
分類程式碼代碼:
12352200
NACRES:
NA.25

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear (Warmed)

儲存溫度

-10 to -25°C

SMILES 字串

N[C@@H](CCCNC(N)=N)C(O)=O.O=C(O)C[C@H]1CCC2=C1NC3=C2C=C(OCC4=CC=C(C5CCCC5)C(C(F)(F)F)=C4)C=C3

生化／生理作用

Etrasimod arginine is an orally available, potent, and selective agonist of Sphingosine-1-Phosphate Receptors 1 (S1PR1). Also, it acts as a partial agonist of S1PR4,5. Etrasimod arginine induces reductions in lymphocyte counts in mice. It is acting as immunosuppressive agents.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Arianna Dal Buono et al.
Biomedicines, 10(7) (2022-07-28)
Inflammatory bowel diseases (IBDs) are chronic and disabling conditions that, uncontrolled, lead to irreversible bowel damage and associated comorbidities. Despite the new era of biological therapies, IBDs remain not curative. The treatment purpose is to induce endoscopic remission, reduce the
Hussien Al-Shamma et al.
The Journal of pharmacology and experimental therapeutics, 369(3), 311-317 (2019-03-16)
Lymphocyte trafficking out of secondary lymphoid organs is regulated by concentration gradient-dependent interactions between the membrane-derived lysophospholipid signaling molecule sphingosine 1-phosphate (S1P) and the G-protein-coupled receptor, S1P1 Etrasimod is a novel, next-generation, small-molecule, oral S1P receptor modulator in clinical development
Matej Zore et al.
Frontiers in microbiology, 13, 926170-926170 (2022-06-24)
New classes of antibiotics are urgently needed in the fight against multidrug-resistant bacteria. Drug repurposing has emerged as an alternative approach to accelerate antimicrobial research and development. In this study, we screened a library of sphingosine-1-phosphate receptor (S1PR) modulators against

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门